Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched control group Clear all
Completed Phase 3 Interventional Results available

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

NCT03585270
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 31, 2026, 12:54 AM EDT
Not yet recruiting Not applicable Interventional

Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain

NCT07513662
View directory record Official record
Conditions
Migraine, Migraine in Adolescence
Interventions
BREATHE with Headache (BREATHE-HA), Enhanced Standard-of-Care: Headache Education
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Progressive Intensity Exercise Training on Glycemic Control in Older Adults

NCT03154073
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
Moderate Intensity Exercise Training (MOD), Vigorous Intensity Exercise Training (VIG)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03248882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Placebo, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
60
States / cities
Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

NCT02959983
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
76
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 31, 2026, 12:54 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery

NCT02320266
View directory record Official record
Conditions
Parkinson's Disease, Essential Tremor, Dystonia, Obsessive Compulsive Disorder
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

NCT00402337
View directory record Official record
Conditions
Chronic Constipation
Interventions
linaclotide acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
60
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program

NCT02384109
View directory record Official record
Conditions
Prediabetic State
Interventions
Shared decision-making with pharmacists, Standard care from primary care providers
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
20
States / cities
Burbank, California • Los Angeles, California • Pacific Palisades, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 31, 2026, 12:54 AM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 31, 2026, 12:54 AM EDT
Not yet recruiting Not applicable Interventional

Self-Compassion, Health, and Empowerment

NCT07733531
View directory record Official record
Conditions
Intimate Partner Violence (IPV), Depression and/or Anxiety Symptoms, PTSD - Post Traumatic Stress Disorder
Interventions
The Self-Compassion, Health, and Empowerment (SHE) Intervention, Health and Nutrition Program
Behavioral
Lead sponsor
Yang Li
Other
Eligibility
18 Years and older · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Watermelon Dose Response Blood Pressure Study

NCT05892328
View directory record Official record
Conditions
Pre-hypertension, Cardiovascular Diseases
Interventions
Watermelon Flesh Dose 1, Watermelon Flesh Dose 2, Control
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
25 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

NCT04026165
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
SEL, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
71
States / cities
Glendale, Arizona • Tucson, Arizona • Canyon Country, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 31, 2026, 12:54 AM EDT
Not listed Not applicable Interventional

Caffeine Study for Pain Control Following Total Joint Replacement

NCT04280263
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Caffeine, Placebo oral tablet
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

NCT00087555
View directory record Official record
Conditions
Fibromyalgia
Interventions
Xyrem (sodium oxybate) oral solution, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
20
States / cities
Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 31, 2026, 12:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy

NCT01048125
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Sympathetic Nerve Activity, Mental Stress Test (Color Word Test), The Modified Oxford Technique for Baroreflex Sensitivity, Cold Pressor Test, Echocardiographic evaluation
Device · Behavioral · Drug + 1 more
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
46
States / cities
Tucson, Arizona • Anaheim, California • Culver City, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821
View directory record Official record
Conditions
Huntington Disease
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Los Alamitos, California • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 31, 2026, 12:54 AM EDT
Completed No phase listed Observational

Study of Heart Transplant Rejection

NCT00042614
View directory record Official record
Conditions
Heart Transplantation
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 12:54 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Improving the Detection, Classification and Treatment of Misaligned Arthritic Ankles

NCT03440008
View directory record Official record
Conditions
Ankle Osteoarthritis
Interventions
Dynamic 3D bone motion capture, wedged insole
Other · Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Not applicable Interventional Results available

Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs

NCT03282890
View directory record Official record
Conditions
Risk Behavior, HIV/AIDS, Medication Adherence, Substance Abuse
Interventions
CHRP-BB
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 31, 2026, 12:54 AM EDT
Completed Phase 3 Interventional Results available

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

NCT00056160
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-5013, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
44
States / cities
Hoover, Alabama • Duarte, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 31, 2026, 12:54 AM EDT